What is the appropriate management for a 69-year-old heavy-alcohol-using patient with a recent seizure, recent fall, and non-adherence to levetiracetam (Keppra)?

Immediate Management: Restart Levetiracetam and Address Alcohol Use Disorder

This patient requires immediate reinitiation of levetiracetam at the prescribed dose (1000 mg BID) with supervised administration, combined with urgent evaluation for alcohol withdrawal syndrome and structured addiction treatment. The combination of ongoing alcohol use, medication non-adherence, recent seizure, and fall creates a high-risk scenario for recurrent seizures, status epilepticus, and sudden unexpected death in epilepsy (SUDEP).

Critical Risk Assessment

This 69-year-old patient faces multiple compounding risks:

• Seizure recurrence risk: Subtherapeutic or absent antiepileptic drug (AED) levels are found in 57-92% of SUDEP cases 1. Non-adherence dramatically increases seizure risk and mortality.

• Alcohol-related seizure risk: The co-occurrence of epilepsy and substance abuse is common, with at least one-third of seizure-related deaths having a history of alcohol use 1. While she has reduced from 2 vodka bottles daily to "a few glasses of wine," she remains at risk for both alcohol withdrawal seizures and breakthrough seizures from her underlying epilepsy.

• Fall risk and injury: The recent fall 2 weeks ago may represent either a seizure, alcohol intoxication, or both. This creates additional risk for traumatic brain injury, which itself can worsen epilepsy 1.

Immediate Action Steps

1. Medication Adherence Strategy

Restart levetiracetam 1000 mg BID immediately 2. The FDA-approved dosing for adults is 1000-3000 mg/day in divided doses, with 1000 mg BID as the standard starting dose 2.

Implement supervised medication administration:

• Daily observed dosing through home health, family member, or outpatient clinic visits
• Use pill boxes with alarms or medication reminder apps
• Consider long-acting injectable alternatives if oral adherence remains impossible (though not available for levetiracetam)

Address barriers to adherence:

• Assess for cognitive impairment from chronic alcohol use (Wernicke-Korsakoff syndrome)
• Screen for depression and suicidal ideation, as levetiracetam carries a black box warning for suicidal thoughts 2
• Evaluate financial barriers to medication access

2. Alcohol Use Disorder Management

Determine current withdrawal risk:

• Calculate time since last drink and quantity consumed
• Assess for withdrawal symptoms: tremors, tachycardia, hypertension, anxiety, diaphoresis
• Use CIWA-Ar scoring if withdrawal symptoms present (score >8 indicates moderate AWS, ≥15 indicates severe AWS) 3

For active alcohol withdrawal syndrome:

Benzodiazepines are first-line treatment 4, 5, 4, 3. Given her age (69 years) and likely hepatic dysfunction from chronic alcohol use:

• Lorazepam is preferred: 1-4 mg PO/IV/IM every 4-8 hours 5. Lorazepam is recommended for elderly patients and those with liver failure because it has no active metabolites and intermediate duration 4, 5, 4.

• Avoid long-acting benzodiazepines (diazepam, chlordiazepoxide) in this elderly patient with probable liver disease, despite their superior seizure prevention, due to accumulation risk 4.

Thiamine supplementation is mandatory:

• 100-300 mg/day for 4-12 weeks for prevention of Wernicke encephalopathy 5
• Must be given BEFORE any IV glucose to prevent precipitating acute thiamine deficiency 5

Carbamazepine as alternative:

• 200 mg PO every 6-8 hours 5
• Effective for seizure prevention in AWS and may be preferred if benzodiazepines are contraindicated 5
• However, requires monitoring for drug interactions with levetiracetam

3. Determine Need for Hospitalization

Inpatient admission is strongly recommended given 5:

• History of withdrawal seizures (2 months ago)
• High levels of recent drinking (previously 2 vodka bottles daily)
• Serious medical comorbidity (recent fall, age 69)
• Medication non-adherence indicating likely failure of outpatient management

Outpatient detoxification is contraindicated in this case despite being more cost-effective in selected patients 5.

4. Psychiatric and Addiction Consultation

Mandatory psychiatric consultation for 5:

• Evaluation and acute management of AWS
• Long-term abstinence planning
• Assessment for co-occurring psychiatric disorders (anxiety, depression, which occur in high prevalence in alcoholics) 4

Coordinate with addiction specialists (psychiatrists, psychologists, social workers) to reduce the treatment gap 4.

Long-Term Management Strategy

Seizure Management

Continue levetiracetam indefinitely as long as she has epilepsy. The initial seizure 2 months ago was likely not solely alcohol-related given the need for ongoing AED therapy. Do not discontinue levetiracetam even if she achieves abstinence, as withdrawal seizures and epilepsy can coexist 1.

Monitor for treatment response:

• Seizure frequency and characteristics
• Medication adherence through pill counts, pharmacy refill records
• Consider checking levetiracetam levels if available, though postmortem levels don't correlate well with antemortem therapeutic levels 1

Levetiracetam is appropriate for this patient because 6:

• Low incidence of hypotension and respiratory depression
• Minimal drug interactions
• Safe profile (nausea and rash are main side effects)
• No hepatotoxicity concerns unlike phenytoin or valproate

Alcohol Abstinence Maintenance

Pharmacotherapy for alcohol use disorder:

Baclofen may be considered as it is the only agent tested in patients with liver disease 3. However, evidence is mixed, with the French ANSM recommending doses not exceeding 80 mg/day 3.

Avoid naltrexone due to hepatotoxicity risk in patients with alcoholic liver disease 4, 5.

Avoid disulfiram due to possible hepatotoxicity in severe ALD 4.

Acamprosate (1,998 mg/day for patients ≥60 kg) has not been tested in cirrhosis but may be considered if liver function is preserved 5.

Psychosocial Interventions

Brief interventions using FRAMES model 5:

• Feedback about dangers of continued drinking
• Responsibility for choices and consequences
• Advice for abstinence
• Menu of alternatives
• Empathy with patient's perspective
• Self-efficacy encouragement

Ongoing support:

• Alcoholics Anonymous or similar peer support groups 5
• Family therapy and education 5
• Community alcohol counseling centers 5
• Regular follow-up to prevent relapse (patients with previous detoxifications have 1.88x higher relapse risk) 7

Critical Pitfalls to Avoid

1. Do not attribute all seizures to alcohol withdrawal: This patient has epilepsy requiring ongoing AED therapy. Alcohol may be a trigger, but she needs levetiracetam regardless of drinking status 1.

2. Do not use phenytoin for alcohol withdrawal seizures: Meta-analysis shows phenytoin is ineffective for secondary prevention of alcohol withdrawal seizures 8. Benzodiazepines are superior 8.

3. Do not discharge without addressing adherence: Non-adherence is the primary issue here. Supervised dosing or inpatient stabilization is essential.

4. Do not overlook fall evaluation: The fall 2 weeks ago requires assessment for head trauma, which could worsen epilepsy or indicate unwitnessed seizure 1.

5. Do not delay thiamine: Give before any glucose-containing IV fluids 5.

6. Monitor for benzodiazepine abuse potential: Limit benzodiazepines to 10-14 days maximum to avoid dependence 3.

Family/Caregiver Role

The relative reporting the history is crucial for success:

• Educate on seizure first aid and when to call 911
• Train in medication administration and monitoring
• Involve in addiction treatment planning
• Provide resources for caregiver support

The prognosis depends entirely on achieving medication adherence and alcohol abstinence. Without both, this patient faces high risk of recurrent seizures, status epilepticus, traumatic injury, and premature death.